This study is in progress, not accepting new patients
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- SpringWorks Therapeutics, Inc.
- ID
- NCT05580770
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 23 people participating
- Last Updated